Emma Walmsley, the departing chief executive of GSK Plc, gave an upbeat forecast for the company’s product portfolio on 29 October, highlighting up to 15 late-stage products that could see a market launch between now and 2031. The company has also upgraded revenue and core operating profit guidance for the current year.
A retrospective analysis published in Nature suggests that people treated for certain cancers, including melanoma and lung cancer, lived significantly longer if they had received an mRNA-based Covid-19 vaccine before or shortly after starting immunotherapy. The findings hint that mRNA vaccines - initially designed to prevent infection - might also amplify anti-cancer immune responses.
Eli Lilly and Company is acquire Adverum Biotechnologies Inc, giving it a Phase 3 gene therapy for a common eye disorder and expanding its portfolio of genetic medicines. The acquisition, priced at approximately $262 million, comes just five months after Lilly made a much bigger outlay for Verve Therapeutics Inc, a Boston, US based company, which has an in vivo gene editing product for cardiovascular disease. This acquisition was valued at $1 billion upfront.
Drug Discovery
Stroke research progresses towards new frontier
By Marc Dechamps
Research Strategy
Redefining drug discovery using quantum physics
By Jarryl D'Oyley and Catherine Stace
Regulation and Policy
Natural history studies underpin clinical research
By Femida Gwadry-Sridhar
Public Policy
EU pharma reform meets US MFN pricing
By Maarten Meulenbelt
Stock Market Performance
Q3 sees unexpected recovery in stocks
By Robin Davison
